PDUFA VI: 'Building Trust' Is Theme Of FDA-Industry Negotiations
Executive Summary
Major achievements of latest drug user fee agreement include focus on drug development cycle, more review time and pilot programs, FDA and industry reps tell DIA meeting.
You may also be interested in...
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.